ArticleWorld journal of gastroenterology2013
Hepatitis C, stigma and cure.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Pooled it
- Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.Health expectations : an international journal of public participation in health care and health policy · 2023Trial
- Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder.Drug and alcohol dependence · 2022Trial
- Stigmatising space-times: Addressing healthcare stigma beyond interpersonal interactions.Health (London, England : 1997) · 2026Article
- Long-term psychological and functional outcomes after hepatitis C eradication with direct-acting antivirals: an 80-month follow-up study.Frontiers in psychiatry · 2026Article
- The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C.Healthcare (Basel, Switzerland) · 2025Article
- Micro-elimination initiative for hepatitis C screening: insight into gender gaps and undiagnosed individuals.Scientific reports · 2025Article
- Perceived discrimination in fatigue: a qualitative interview study in the SOMA.SOC project.Frontiers in sociology · 2025Article
- Article
- Exploring the Perspectives of Unhoused Adults and Providers Across the HCV Care Continuum.Clinical nursing research · 2024Article
- [The status of national and global hepatitis C elimination].Innere Medizin (Heidelberg, Germany) · 2024Review
- An Analysis of Social Determinants of Health and Their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore.Open forum infectious diseases · 2024Article
- Hepatitis C (HCV) prevalence in citizens of the Métis Nation of Ontario.BMC infectious diseases · 2024Article
- Causal associations between chronic viral hepatitis and psychiatric disorders: a Mendelian randomization study.Frontiers in psychiatry · 2024Article
- Challenges Facing Viral Hepatitis C Elimination in Lebanon.Pathogens (Basel, Switzerland) · 2023Review
- [Strategietreffen: Virushepatitis in Deutschland eliminieren].Zeitschrift fur Gastroenterologie · 2023Article
- Social determinants of health derived from people with opioid use disorder: Improving data collection, integration and use with cross-domain collaboration and reproducible, data-centric, notebook-style workflows.Frontiers in medicine · 2023Article
- Liver Diseases in South Korea: A Pulse Check of the Public's Knowledge, Awareness, and Behaviors.Yonsei medical journal · 2022Article
- In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Healthcare stigma and HIV risk among rural people who inject drugs.Drug and alcohol dependence · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The infection with hepatitis C virus (HCV) is one of the most important global chronic viral infections worldwide. It is estimated to affect around 3% of the world population, about 170-200 million people. Great part of the infections are asymptomatic, the patient can be a chronic carrier for decades without knowing it. The most severe consequences of the chronic infection are liver cirrhosis and hepatocellular carcinoma, which appears in 20%-40% of the patients, leading to hepatic failure and death. The HCV was discovered 25 years ago in 1989, is a RNA virus and classified by the World Health Organization as an oncogenic one. Hepatocellular carcinoma is one of the most important cancers, the fifth worldwide in terms of mortality. It has been increasing in the Ocidental world, mainly due to chronic hepatitis C. Hepatitis C is not only a liver disease and a cause of cirrhosis, but also a mental, psychological, familiar, and social disease. The stigma that the infected person sometimes carries is tremendous having multiple consequences. The main cause is lack of adequate information, even in the health professionals setting. But, besides the "drama" of being infected, health professionals, family, society and the infected patients, must be aware of the chance of real cure and total and definitive elimination of the virus. The treatment for hepatitis C has begun in the last 80's with a percentage of cure of 6%. Step by step the efficacy of the therapy for hepatitis C is rapidly increasing and nowadays with the very new medications, the so called Direct Antiviral Agents-DAAs of new generation, is around 80%-90%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.